DeChanta Vaughan, Contract Specialist

DeChanta Vaughan serves as a Contract Specialist within the National Cancer Institute (NCI), part of the National Institutes of Health, where she plays a critical role in executing complex research and development acquisitions aligned with the agency’s mission to advance cancer diagnostics, therapeutics, and precision medicine. She manages the full lifecycle of procurement actions for high-technical-service contracts, ensuring compliance with federal acquisition regulations while supporting cutting-edge scientific innovation. Her portfolio primarily encompasses research services, laboratory infrastructure support, and analytical technology procurement, enabling NCI’s mission-critical scientific programs through timely and compliant contracting solutions. Vaughan maintains a consistent working relationship with Roche Diagnostics Corporation, a key contractor providing advanced diagnostic platforms and life sciences tools critical to NCI’s translational research initiatives. Her procurement approach reflects a preference for established industry partners with proven technical capabilities in molecular diagnostics and genomic analysis, while maintaining an open pipeline for innovative small business solutions. Her vendor engagements emphasize performance-based outcomes, technical rigor, and adherence to federal compliance standards. Her contracting patterns reveal a strong preference for open competition, with 83.3% of awards issued without set-aside designations, reflecting a focus on technical merit and capability over socioeconomic categorization. Nevertheless, she actively supports small business participation, with 16.7% of awards designated as total small business set-asides under FAR 19.5, demonstrating a balanced commitment to both operational efficiency and socioeconomic goals. Vaughan’s primary procurement focus lies in NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences), where she secures specialized services in genomic sequencing, biomarker validation, and clinical data analysis. She also procures broader scientific and technical services under NAICS 541990, including bioinformatics, laboratory management, and regulatory compliance support. Her expertise centers on high-complexity, science-driven acquisitions that require deep domain knowledge in oncology research and biotechnology infrastructure.